Lanicemine Explained

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression.[1] [2] Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects.[3] However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.[4]

See also

Notes and References

  1. Web site: Lanicemine. AdisInsight. 18 June 2017. en.
  2. Machado-Vieira R, Henter ID, Zarate CA . New targets for rapid antidepressant action . Progress in Neurobiology . 152 . 21–37 . May 2017 . 26724279 . 4919246 . 10.1016/j.pneurobio.2015.12.001 .
  3. Zarate CA, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA . 6 . A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression . Biological Psychiatry . 74 . 4 . 257–64 . August 2013 . 23206319 . 3594049 . 10.1016/j.biopsych.2012.10.019 .
  4. Web site: Flowers. Sophie . vanc . Return to growth: AstraZeneca's CEO Pascal Soriot says 2013 was year of "momentum" for the company. 6 February 2014.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lanicemine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.